We are the Japanese largest cancer center providing exceptional care, innovative research & outstanding educational programs.
English website of NCCRI Japan →
国立がん研究センター研究所公認Twitterアカウントを開設して2年になりました🎉
これまで多くの皆様にフォローして頂き、ありがとうございます。
引き続きどうぞよろしくお願い致します‼️
Do you remember when you joined Twitter? I do!
#MyTwitterAnniversary
Nature誌のNature Cancer Indexに当研究所の紹介記事が掲載されました。
Our Research Institute
@NccriOfficial
is now introduced in the Nature Cancer Index in the 7 September 2023 issue of
@Nature
.
[Research] The paper from Lab of Genome Stress Signaling (Shiotani lab) is now online, revealing a crucial role of ATR-PrimPol in enabling precancerous cells to survive KRAS-induced replication stress and expand clonally with genomic instability.
「Research」The paper to introduce the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) and the Japanese platform for cancer genomic medicine is now online
@CD_AACR
.
[Notice]The recent paper "Oncogenic structural aberration landscape in gastric cancer genomes", led by Mihoko Saito-Adachi and Tatsuhiro Shibata at the Cancer Genomics Research Division, has been chosen to feature on the Nature Communications Editors’ Highlights (Cancer) Webpage!
[Press Release] A research group led by
@friend1_ws
and
@kataoka_lab
has developed novel software to detect somatic structural variations (SVs) using long-read and demonstrated that complex SVs could be effectively identified (
@NAR_open
).
[Research] The paper from Division of Cellular Signaling is now online
@AGA_Gastro
, providing the results of mutational analysis of HLA class I genes in microsatellite instable colorectal cancer with long-read sequencer
@PacBio
.
[Press Release]
@Nature
Dr. Pasi A. Jänne group at Dana-Farber Cancer Institute and Dr. Yoshihisa Kobayashi, Div. of Molecular Pathology at National Cancer Center Japan discovered the splicing vulnerability and novel therapy in RAS Q61 cancers.
【Press release】World's Largest Whole Genome Sequencing of Renal Cancer
Mutational signature linked to an unknown exposure discovered in 70% of Japanese samples
[Honor]
Congratulations Dr. Hiroyoshi Nishikawa for being named a 2022 Highly Cited Researcher!
腫瘍免疫分野の西川博嘉先生がClarivateの 2022 Highly Cited Researcherに選出されました。おめでとうございます!
@ClarivateAG
#HighlyCited2022
【受賞】
がんRNA研究分野
@YoshimiLab
の吉見昭秀さんが「リバネス研究アワード2023 先端研究推進部門」を受賞しました。
おめでとうございます🎉
[Award]
Congratulations
@AkihideYoshimi
for being awarded the "Leave a Nest" Research Award 2023!!
[Press Release] Out in
@Nature
today!
International collaborative team of Dr. Savvas Savvides group
@ResearchUGent
@VIBLifeSciences
and
@YoshimiLab
at National Cancer Center Japan 🇧🇪🇯🇵 discovered the structure and activation mechanism of ALK!
[Press Release] The efficacy of trastuzumab deruxtecan in the treatment of uterine carcinosarcoma, a rare cancer, has been demonstrated both IIT and preclinical study at the NCCH and NCCRI. The NCC will continue to make concerted efforts to drug development for rare cancers.